ClearPoint Neuro Q3 revenue misses estimates
CLPT•ClearPoint Neuro's third-quarter revenue rose 36% year over year to $12.1 million, below the $12.30 million consensus estimate. The company reported a 58% gross margin, raised $22 million through an equity offering and ended the quarter with $46.2 million in cash.
1. Revenue and margins
Third-quarter revenue increased 36% year over year to $12.1 million, missing the $12.30 million estimate. Gross margin fell to 58% from 63%, which the company attributed to new lab overhead and amortization costs.
2. Growth drivers and outlook
Revenue growth in neurosurgery navigation and therapy was primarily driven by additional sales from the acquired IRRAflow product. Record capital equipment and software revenue reflected increased placements of navigation systems, IRRAflow control units and Prism laser units; biologics and drug delivery revenue rose mainly on higher services revenue from ClearPoint Advanced Laboratories. ClearPoint Neuro now estimates 2026 revenue of $48.0 million to $50.0 million.
3. Cash and expenses
The company raised $22 million from an equity offering and ended the quarter with $46.2 million in cash. Third-quarter operating expenses were $13.4 million.
